These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38039314)

  • 1. Seroprevalence of human adenovirus type 5 neutralizing antibodies in the Philippines.
    Francisco AG; Reyes JCB; Tabios IKB; Cruz CJG; Ang MAC; Heralde FM; Lacuna ARG; de Paz-Silava SLM
    PLoS One; 2023; 18(12):e0293046. PubMed ID: 38039314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels during the SARS-CoV-2 Pandemic.
    Wang X; Kerkmann L; Hetzel M; Windmann S; Trilling M; Zhang W; Ehrhardt A; Bayer W
    J Virol; 2022 Nov; 96(22):e0113322. PubMed ID: 36342295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, China.
    Tian X; Fan Y; Wang C; Liu Z; Liu W; Xu Y; Mo C; You A; Li X; Rong X; Zhou R
    Virol Sin; 2021 Jun; 36(3):373-381. PubMed ID: 33165772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China.
    Yi H; Wang Q; Deng J; Li H; Zhang Y; Chen Z; Ji T; Liu W; Zheng X; Ma Q; Sun X; Zhang Y; Yu X; He M; Chen L; Feng Y
    Virol Sin; 2022 Oct; 37(5):716-723. PubMed ID: 35764207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of 65 years of human adenovirus seroprevalence.
    Mennechet FJD; Paris O; Ouoba AR; Salazar Arenas S; Sirima SB; Takoudjou Dzomo GR; Diarra A; Traore IT; Kania D; Eichholz K; Weaver EA; Tuaillon E; Kremer EJ
    Expert Rev Vaccines; 2019 Jun; 18(6):597-613. PubMed ID: 31132024
    [No Abstract]   [Full Text] [Related]  

  • 6. A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55.
    Liu T; Zhou Z; Tian X; Liu W; Xu D; Fan Y; Liao J; Gu S; Li X; Zhou R
    Vaccine; 2018 Apr; 36(16):2199-2206. PubMed ID: 29548605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Patients with Neuromuscular Disorders.
    Klann PJ; Wang X; Elfert A; Zhang W; Köhler C; Güttsches AK; Jacobsen F; Weyen U; Roos A; Ehrke-Schulz E; Ehrhardt A; Vorgerd M; Bayer W
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
    Zhao H; Xu C; Luo X; Wei F; Wang N; Shi H; Ren X
    Front Immunol; 2018; 9():335. PubMed ID: 29563911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa.
    Wang B; Li J; Wu S; Chen Y; Zhang Z; Zhai Y; Guo Q; Zhang J; Song X; Zhao Z; Hou L; Chen W
    Emerg Microbes Infect; 2018 Dec; 7(1):200. PubMed ID: 30514848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Critical and Conformational Neutralizing Epitope in Human Adenovirus Type 4 Hexon.
    Tian X; Qiu H; Zhou Z; Wang S; Fan Y; Li X; Chu R; Li H; Zhou R; Wang H
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of neutralizing monoclonal antibodies against a conformational epitope of human adenovirus type 7 (HAdv-7) incorporated in capsid encoded in a HAdv-3-based vector.
    Liu M; Tian X; Li X; Zhou Z; Li C; Zhou R
    PLoS One; 2014; 9(7):e103058. PubMed ID: 25054273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: "Adenovirus Vaccine Within an Adenovirus Vector".
    Yan Y; Jing S; Feng L; Zhang J; Zeng Z; Li M; Zhao S; Ou J; Lan W; Guan W; Wu X; Wu J; Seto D; Zhang Q
    Virol Sin; 2021 Jun; 36(3):354-364. PubMed ID: 32458297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.
    Li Q; Liu Q; Huang W; Song A; Zhao C; Wu J; Wang Y
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.
    Dudareva M; Andrews L; Gilbert SC; Bejon P; Marsh K; Mwacharo J; Kai O; Nicosia A; Hill AV
    Vaccine; 2009 Jun; 27(27):3501-4. PubMed ID: 19464527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing epitopes mapping of human adenovirus type 14 hexon.
    Ma Q; Tian X; Jiang Z; Huang J; Liu Q; Lu X; Luo Q; Zhou R
    Vaccine; 2015 Nov; 33(48):6659-65. PubMed ID: 26546264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Pre-Existing Neutralizing Antibody to Human Adenovirus Types 5 and 49 and Simian Type 23 in Chinese Population.
    Zou P; Wang Q; Zhang P; Luo S; Wang C; Zhang E; Zhang L; Li C; Li T
    Viral Immunol; 2023 Nov; 36(9):617-625. PubMed ID: 37903228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions.
    Qiu H; Li X; Tian X; Zhou Z; Xing K; Li H; Tang N; Liu W; Bai P; Zhou R
    J Virol; 2012 Aug; 86(15):7964-75. PubMed ID: 22623776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human AdV-20-42-42, a Promising Novel Adenoviral Vector for Gene Therapy and Vaccine Product Development.
    Ballmann MZ; Raus S; Engelhart R; Kaján GL; Beqqali A; Hadoke PWF; van der Zalm C; Papp T; John L; Khan S; Boedhoe S; Danskog K; Frängsmyr L; Custers J; Bakker WAM; van der Schaar HM; Arnberg N; Lemckert AAC; Havenga M; Baker AH
    J Virol; 2021 Oct; 95(22):e0038721. PubMed ID: 34469243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.
    Yang WX; Zou XH; Jiang SY; Lu NN; Han M; Zhao JH; Guo XJ; Zhao SC; Lu ZZ
    Vaccine; 2016 Nov; 34(46):5579-5586. PubMed ID: 27682509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroprevalence of neutralizing antibodies to human mastadenovirus serotypes 3 and 7 in healthy children from guangdong province.
    Kuang L; Wang C; Chen H; Li Y; Liang Z; Xu T; Guo M; Zhu B
    Heliyon; 2023 Jun; 9(6):e16986. PubMed ID: 37346335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.